RMTI Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
19.1M
+7.5%
17.8M
+2.6%
17.3M
-5.5%
18.3M
+15.2%
15.9M
Cost of Revenue
16.0M
+10.1%
14.5M
+0.7%
14.4M
-0.2%
14.5M
+6.0%
13.7M
Gross Profit
3.1M
-4.1%
3.2M
+11.9%
2.9M
-25.3%
3.9M
+70.7%
2.3M
Operating Expenses
5.3M
+23.9%
4.3M
-1.7%
4.4M
+2.4%
4.3M
+10.9%
3.9M
R&D
114.0K
+185.0%
40.0K
0
0
0
SG&A
4.4M
+2.5%
4.3M
-2.6%
4.4M
+2.4%
4.3M
+10.9%
3.9M
Operating Income
-2221000
-109.3%
-1061000
+28.3%
-1480000
-271.9%
-398000
+74.9%
-1584000
EBITDA
-824000
-44.8%
-569000
+41.3%
-969000
-754.7%
148.0K
+114.2%
-1040000
Net Income
-2324000
-98.3%
-1172000
+27.0%
-1605000
-189.7%
-554000
+68.4%
-1753000
EPS (Basic)
$-0.59
-73.5%
$-0.34
+15.0%
$-0.40
-185.7%
$-0.14
+71.4%
$-0.49
EPS (Diluted)
$-0.59
-73.5%
$-0.34
+15.0%
$-0.40
-185.7%
$-0.14
+71.4%
$-0.49
Shares (Diluted)
4.0M
+0.3%
4.0M
+0.4%
3.9M
-0.1%
3.9M
+9.5%
3.6M
Rockwell Medical, Inc. (DE) (RMTI) — Financials